US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

ホーム
投資
株式
アメリカ
USOTC
NZX (PK) (NZSTF) 銘柄情報

NZX (PK) (NZSTF)

0.7652

0.00

(0.00%)

終了 6月16日 5:00AM

NZX (PK) (NZSTF) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.7652

( - )

買値

0.7407

売値

0.8997

出来高

-

0.00 日の範囲 0.00

0.7652 52 週間の範囲 0.9054

時価総額

前日終値

0.7652

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 386,235

発行済株式数

329,241,123

配当利回り

0.06 (4.70%)

PER

21.63

1 株当たり利益 (EPS)

0.06

歳入

128.95M

純利益

21.48M

NZX Limited operates a stock exchange in New Zealand. The company operates through five segments: Capital Markets Origination, Secondary Markets, Information Services, Funds Management, and Wealth Technologies. The Capital Markets Origination segment provides issuer services for current and prospect... NZX Limited operates a stock exchange in New Zealand. The company operates through five segments: Capital Markets Origination, Secondary Markets, Information Services, Funds Management, and Wealth Technologies. The Capital Markets Origination segment provides issuer services for current and prospective customers. The Secondary Markets segment provides trading and post-trade services for securities and derivatives markets, as well as provides central securities depository; and acts as a market operator for Fonterra Co-Operative Group, the Electricity Authority, and the Ministry for the Environment. The Information Services segment provides information services for the securities and derivatives markets, and analytics for the dairy sector. The Funds Management segment manages funds, such as KiwiSaver, superannuation, managed funds, and exchange traded funds. The Wealth Technologies segment provides funds administration and custodian services. The company was formerly known as New Zealand Exchange Limited and changed its name to NZX Limited in July 2008. NZX Limited was founded in 1866 and is headquartered in Wellington, New Zealand. 詳細を表示

セクター

Finance

業界

Capital Markets

ウェブサイト

www.nzx.com

本社

Wellington, New Zealand

設立

1866

NZX (PK) is listed in the Finance sector of the その他OTC with ticker NZSTF. The last closing price for NZX (PK) was US$0.77. Over the last year, NZX (PK) shares have traded in a share price range of US$ 0.7652 to US$ 0.9054.

NZX (PK) currently has 329,241,123 shares in issue. The market capitalisation of NZX (PK) is US$251.94 million. NZX (PK) has a price to earnings ratio (PE ratio) of 21.63.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	-0.038364	-4.77423080178	0.803564	0.803564	0.7652	10000	0.784382	CS
12	-0.06	-7.27096461464	0.8252	0.8252	0.7652	7557	0.79866663	CS
26	-0.111445	-12.712671606	0.876645	0.9054	0.7652	4126	0.81161279	CS
52	-0.1044	-12.0055197792	0.8696	0.9054	0.7652	2048	0.81541579	CS
156	0.0528	7.41156653565	0.7124	1.103887	0.557036	2164	0.77982937	CS
260	-0.6098	-44.3490909091	1.375	1.375	0.557036	2265	0.83604469	CS

NZSTF - Frequently Asked Questions (FAQ)

What is the current NZX (PK) share price?

The current share price of NZX (PK) is US$ 0.7652

How many NZX (PK) shares are in issue?

NZX (PK) has 329,241,123 shares in issue

What is the market cap of NZX (PK)?

The market capitalisation of NZX (PK) is USD 251.94M

What is the 1 year trading range for NZX (PK) share price?

NZX (PK) has traded in the range of US$ 0.7652 to US$ 0.9054 during the past year

What is the PE ratio of NZX (PK)?

The price to earnings ratio of NZX (PK) is 21.63

What is the cash to sales ratio of NZX (PK)?

The cash to sales ratio of NZX (PK) is 3.56

What is the registered address of NZX (PK)?

The registered address for NZX (PK) is NZX Centre, Wellington, 6011

What is the NZX (PK) website address?

The website address for NZX (PK) is www.nzx.com

Which industry sector does NZX (PK) operate in?

NZX (PK) operates in the Capital Markets sector

Homework.Investwell

Homework.Investwell 8分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 17分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 20分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 25分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 29分前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 29分前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 37分前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

biotechinvestor1

biotechinvestor1 40分前

I love it when Alteogen fanboys post on this board. Nearly every time they show up, Halozyme has a run up.

DR_rugby

DR_rugby 40分前

Prophecy is coming

https://www.cnbc.com/2026/06/16/boj-rate-hike-historic-inflation.html

Japanese rates are going higher

Yen is yet to be stabilize

The great unwinding is coming soon

GLTA

BigBadWolf

BigBadWolf 47分前

Authorized Shares 1,800,000,000 06/15/2026
Outstanding Shares 1,619,034,363 06/15/2026 >5m
Restricted 480,530,670 06/15/2026 >5m
Unrestricted 1,138,503,693 06/15/2026
Held at DTC 1,011,499,104 06/15/2026 >8m

Authorized Shares 1,800,000,000 06/05/2026

4retire

4retire 50分前

One has to question why a “cash rich” company would need to raise $20-25 billion by going to bond sales that will be in 7 tranches, ranging from 2 to 30 years. The statement is that it’s for general purposes and to redo some current debt financing.

Based on recent financials, NVDA’

tank777

tank777 51分前

FACT CHECK:

The key distinction is between “eligible” and “selected.”

To date, CMS has not publicly released a list of approved CBD brands for the Substance Access Beneficiary Engagement Incentive (BEI) program.

That means:

Mr. Tate

Mr. Tate 51分前

Your Mother should've named you loser0. Awww did someone take your lunch money in school loser0? IMO

jhdf51

jhdf51 51分前

Great.. thank you.

ducci1

ducci1 52分前

Pivot Calcs: SPX Pivot 7549---R1 7582---S1 7521---SPY Pivot 754---R1 757---S1 752----ES Pivot 7601---R1 7667---S1 7555----VIX Pivot 16.35---R1 16.70---S1 15.85---15 min Bull/Bear R/Line 18.34!----!!LOL!!

Mr. Tate

Mr. Tate 52分前

Are you for real loser0? You always hide behind a computer screen loser0? IMO

Wolf-man jack

Wolf-man jack 57分前

WQLF SAYS: .Charlottes Web products Have Not been PUBLICLY STATED as being OFFICIALLY APPROVED. In the case of CV SCIENCES, the CMS Pilot Program still has time to Announce CV SCIENCES or are they already enrolled? Cornbread was never announced, so one can not reliably state that it is A True FACT Y

knrorrel

knrorrel 1時間前

Wow, that would be fantastic. It would be a dream come true for me after the many losses (FORW, BLEG, PAVS) this year... I have to admit, the latest news was fantastic; the company shouldn't be trading at this level and could soon see a massive surge—similar to how QBTS went from $0.50 to $20 years

First Trust FactorFX ETF

FTSE Developed Europe La...

Per Aarsleff Holding AS

DJ Americas Industrials ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。